Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration
Purpose: To compare verteporfin photodynamic therapy combined with intravitreal ranibizumab (combination therapy) versus ranibizumab monotherapy for management of neovascular age-related macular degeneration. Methods: Thirty patients (40 eyes) with neovascular age-related macular degeneration were p...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| التنسيق: | article |
| منشور في: |
2011
|
| الوصول للمادة أونلاين: | http://hdl.handle.net/10725/14185 https://doi.org/10.1097/IAE.0b013e3181fe54ab http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://journals.lww.com/retinajournal/fulltext/2011/04000/RANIBIZUMAB_MONOTHERAPY_VERSUS_SINGLE_SESSION.2.aspx?casa_token=mSj2BKpTRfIAAAAA:iCQEkhnTNgCgUy2-riXihlrYAJYEnSTm_k7VCZ1LkTypvjjJxedT-wFeN-oGo9Og4wPe1belgY-Kb3dmDneKaKs |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513469176348672 |
|---|---|
| author | Bashshur, Ziad F. |
| author2 | Schakal, Alex R. El-Mollayess, Georges M. Arafat, Samer Jaafar, Dalida Salti, Haytham I. |
| author2_role | author author author author author |
| author_facet | Bashshur, Ziad F. Schakal, Alex R. El-Mollayess, Georges M. Arafat, Samer Jaafar, Dalida Salti, Haytham I. |
| author_role | author |
| dc.creator.none.fl_str_mv | Bashshur, Ziad F. Schakal, Alex R. El-Mollayess, Georges M. Arafat, Samer Jaafar, Dalida Salti, Haytham I. |
| dc.date.none.fl_str_mv | 2011 2022-11-01T12:29:30Z 2022-11-01T12:29:30Z 2022-11-01 |
| dc.identifier.none.fl_str_mv | 0275-004X http://hdl.handle.net/10725/14185 https://doi.org/10.1097/IAE.0b013e3181fe54ab Bashshur, Z. F., Schakal, A. R., El-Mollayess, G. M., Arafat, S., Jaafar, D., & Salti, H. I. (2011). Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration. Retina, 31(4), 636-644. http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://journals.lww.com/retinajournal/fulltext/2011/04000/RANIBIZUMAB_MONOTHERAPY_VERSUS_SINGLE_SESSION.2.aspx?casa_token=mSj2BKpTRfIAAAAA:iCQEkhnTNgCgUy2-riXihlrYAJYEnSTm_k7VCZ1LkTypvjjJxedT-wFeN-oGo9Og4wPe1belgY-Kb3dmDneKaKs |
| dc.language.none.fl_str_mv | en |
| dc.relation.none.fl_str_mv | RETINA, The Journal of Retinal and Vitreous Diseases |
| dc.rights.*.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.title.none.fl_str_mv | Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration |
| dc.type.none.fl_str_mv | Article info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/article |
| description | Purpose: To compare verteporfin photodynamic therapy combined with intravitreal ranibizumab (combination therapy) versus ranibizumab monotherapy for management of neovascular age-related macular degeneration. Methods: Thirty patients (40 eyes) with neovascular age-related macular degeneration were prospectively allocated to combination therapy or monotherapy. In monotherapy, the induction phase consisted of 3 consecutive monthly ranibizumab injections (0.5 mg), while the combination therapy had a single session of photodynamic therapy with intravitreal ranibizumab. Follow-up treatment for either group consisted only of additional as-needed ranibizumab injections. The main outcome measure was that a proportion of eyes losing <15 letters of visual acuity after 12 months. Results: Except for 1 eye in combination therapy, all eyes in both groups lost <15 letters of visual acuity. At 12 months, there was a mean gain of +12 letters and +3.2 letters for monotherapy and combination therapy, respectively (relative percent change of 32% vs. 7%, P = 0.03). Anatomical improvement was similar in both groups. After induction, the time until ranibizumab retreatment was longer for combination therapy (P = 0.002) while ranibizumab injections were required more frequently with monotherapy (P = 0.015). Conclusion: Ranibizumab monotherapy showed greater improvement in visual acuity versus combination therapy. However, combination therapy required fewer ranibizumab injections. Larger trials need to confirm the findings of this pilot study. |
| eu_rights_str_mv | openAccess |
| format | article |
| id | LAURepo_4da462278400be32ea58ba1ecc69de3b |
| identifier_str_mv | 0275-004X Bashshur, Z. F., Schakal, A. R., El-Mollayess, G. M., Arafat, S., Jaafar, D., & Salti, H. I. (2011). Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration. Retina, 31(4), 636-644. |
| language_invalid_str_mv | en |
| network_acronym_str | LAURepo |
| network_name_str | Lebanese American University repository |
| oai_identifier_str | oai:laur.lau.edu.lb:10725/14185 |
| publishDate | 2011 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| spelling | Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degenerationBashshur, Ziad F.Schakal, Alex R.El-Mollayess, Georges M.Arafat, SamerJaafar, DalidaSalti, Haytham I.Purpose: To compare verteporfin photodynamic therapy combined with intravitreal ranibizumab (combination therapy) versus ranibizumab monotherapy for management of neovascular age-related macular degeneration. Methods: Thirty patients (40 eyes) with neovascular age-related macular degeneration were prospectively allocated to combination therapy or monotherapy. In monotherapy, the induction phase consisted of 3 consecutive monthly ranibizumab injections (0.5 mg), while the combination therapy had a single session of photodynamic therapy with intravitreal ranibizumab. Follow-up treatment for either group consisted only of additional as-needed ranibizumab injections. The main outcome measure was that a proportion of eyes losing <15 letters of visual acuity after 12 months. Results: Except for 1 eye in combination therapy, all eyes in both groups lost <15 letters of visual acuity. At 12 months, there was a mean gain of +12 letters and +3.2 letters for monotherapy and combination therapy, respectively (relative percent change of 32% vs. 7%, P = 0.03). Anatomical improvement was similar in both groups. After induction, the time until ranibizumab retreatment was longer for combination therapy (P = 0.002) while ranibizumab injections were required more frequently with monotherapy (P = 0.015). Conclusion: Ranibizumab monotherapy showed greater improvement in visual acuity versus combination therapy. However, combination therapy required fewer ranibizumab injections. Larger trials need to confirm the findings of this pilot study.Published2022-11-01T12:29:30Z2022-11-01T12:29:30Z20112022-11-01Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article0275-004Xhttp://hdl.handle.net/10725/14185https://doi.org/10.1097/IAE.0b013e3181fe54abBashshur, Z. F., Schakal, A. R., El-Mollayess, G. M., Arafat, S., Jaafar, D., & Salti, H. I. (2011). Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration. Retina, 31(4), 636-644.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://journals.lww.com/retinajournal/fulltext/2011/04000/RANIBIZUMAB_MONOTHERAPY_VERSUS_SINGLE_SESSION.2.aspx?casa_token=mSj2BKpTRfIAAAAA:iCQEkhnTNgCgUy2-riXihlrYAJYEnSTm_k7VCZ1LkTypvjjJxedT-wFeN-oGo9Og4wPe1belgY-Kb3dmDneKaKsenRETINA, The Journal of Retinal and Vitreous Diseasesinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/141852022-11-01T12:29:43Z |
| spellingShingle | Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration Bashshur, Ziad F. |
| status_str | publishedVersion |
| title | Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration |
| title_full | Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration |
| title_fullStr | Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration |
| title_full_unstemmed | Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration |
| title_short | Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration |
| title_sort | Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration |
| url | http://hdl.handle.net/10725/14185 https://doi.org/10.1097/IAE.0b013e3181fe54ab http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php https://journals.lww.com/retinajournal/fulltext/2011/04000/RANIBIZUMAB_MONOTHERAPY_VERSUS_SINGLE_SESSION.2.aspx?casa_token=mSj2BKpTRfIAAAAA:iCQEkhnTNgCgUy2-riXihlrYAJYEnSTm_k7VCZ1LkTypvjjJxedT-wFeN-oGo9Og4wPe1belgY-Kb3dmDneKaKs |